LG-ESS frequently expresses receptors for estrogen and progesterone and, on this basis, various hormonal therapy regimens (gestagens, GnRH analogs, or aromatase inhibitors) have been proposed over time, but the results reported so far are based on very heterogeneous small retrospective series and there is no consensus on the effectiveness of these treatments (42). This evidence concerns the gene GNRH1 and endometrioid stromal sarcoma.